Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).

导出原文传递

翻译打印收藏纠错

第一作者： Umberto,Basso

第一单位： Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.

作者： Umberto,Basso ^[1] ; Giuseppe,Procopio ^[2] ; Giuseppe,Fornarini ^[3] ; Francesco,Massari ^[4] ; Alessandra,Bearz ^[5] ; Lucia,Fratino ^[5] ; Michele,Milella ^[6] ; Maria,Bassanelli ^[7] ; Paola,Ermacora ^[8] ; Davide,Bimbatti ^[9] ; Elena,Verzoni ^[2] ; Mimma,Rizzo ^[10] ; Camillo,Porta ^[11]

作者单位： Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy. ^[1] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[2] Medical Oncology Unit 1, Ospedale Policlinico San Martino IRCCS, Genova, Italy. ^[3] Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria, Bologna, Italy. ^[4] Medical Oncology Unit, Centro di Riferimento Oncologico CRO IRCCS, Aviano, Italy. ^[5] Medical Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. ^[6] Medical Oncology Unit, Ospedale San Camillo de Lellis Hospital, Rieti, Italy. ^[7] Department of Oncology, Azienda Ospedaliero-Universitaria S. M. della Misericordia, Udine, Italy. ^[8] Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCSS, Padova, Italy. ^[9] Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy. ^[10] Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.;Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy. ^[11]

关键词 Hypertension Metastatic renal cell carcinoma Progression Retrospective Survival Tivozanib Toxicity